Liquid Biopsy for Early Pancreatic Cancer Detection: Why Has It Not Yet Worked?

Area of Science:

• Oncology
• Biomarkers
• Diagnostic Technologies

Background:

• Liquid biopsy, analyzing circulating tumor DNA (ctDNA) and other markers, is explored for early pancreatic ductal adenocarcinoma (PDA) detection.
• Current methods using peripheral blood face limitations in sensitivity and specificity for early-stage PDA and precursor lesions.

Purpose of the Study:

• To critically review the barriers hindering the clinical utility of liquid biopsy for early PDA detection.
• To identify biological, technical, and clinical challenges that impede reliable early diagnosis.

Main Methods:

• Review of existing literature on liquid biopsy approaches for PDA.
• Analysis of circulating tumor-derived components (cfDNA, cfRNA, EVs, CTCs) and pancreas-associated fluids.
• Examination of biological factors (tumor burden, shedding) and technical issues (standardization, reproducibility).

Main Results:

• Early PDA and precursor lesions have minimal tumor burden and low analyte shedding, creating significant detection challenges.
• Multilayered liquid biopsy approaches and pancreas-associated fluid analysis have not consistently improved diagnostic performance.
• Concerns exist regarding overdiagnosis due to molecular alterations reflecting clonal expansion without inevitable malignancy.

Conclusions:

• Liquid biopsy is currently a complementary tool, not a replacement for histopathology in early PDA detection.
• Biological and technical hurdles, alongside pre-analytical variability, must be addressed for meaningful clinical application.
• The precise role of liquid biopsy in early PDA detection remains undefined, requiring further research to overcome existing barriers.